About Us
Inhibitors
In some patients, the immune system develops antibodies (called inhibitors) against the infused clotting factor. These inhibitors neutralize the effect of the treatment, making the standard factor replacement less effective or even useless. This is one of the most serious complications of hemophilia treatment.
Why Do Inhibitors Develop? (Causes)
The main reason is that the immune system recognizes the infused clotting factor as a “foreign protein” and produces antibodies against it.Factors that increase the risk of inhibitor development include:
Genetic factors – Certain mutations in the F8 or F9 gene.
Severity of hemophilia – Inhibitors are more common in severe hemophilia patients.
Ethnicity – Higher risk in some ethnic groups (e.g., African and Hispanic populations).
Treatment-related factors –
1-Type of factor product used (plasma-derived vs recombinant).
2-Frequency and dose of infusions.
3-Intensive treatment during surgeries or severe bleeds.
When Do Inhibitors Develop?
Most often within the first 50 exposure days (the first 50 times a patient receives factor infusion).
They can also develop later in life, especially if the patient undergoes intensive treatment or surgery.
In mild or moderate hemophilia, inhibitors may develop later in adulthood, sometimes after factor treatment for surgery or trauma.
How Do Inhibitors Affect Patients?
Standard factor replacement therapy becomes ineffective.
Bleeding episodes become harder to control.
Patients may suffer from more joint bleeds, muscle bleeds, or life-threatening bleeds.
Treatment becomes more complicated and expensive.
How Are Inhibitors Diagnosed?
Through a blood test called the Bethesda Assay, which measures the strength (titer) of inhibitors.
Inhibitors are classified as:
1- Low titer – respond to higher doses of factor.
2- High titer – do not respond, requiring alternative therapies.
How Are Inhibitors Treated/Managed?
Bypassing agents (instead of factor VIII or IX):
1- Recombinant Activated Factor VII (rFVIIa)
2- Activated Prothrombin Complex Concentrate (aPCC) These help the body clot without depending on the inhibited factor.
Immune Tolerance Induction (ITI):
1- Repeatedly giving high doses of factor to “train” the immune system to accept it.
2- This can take months to years but may eliminate inhibitors permanently.
Newer Therapies:
1- Emicizumab (Hemlibra): A non-factor therapy for Hemophilia A with or without inhibitors.
2- Gene therapy (in clinical trials) may provide long-term solutions in the future.
